Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.
about
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey.RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.Retrospective Multicenter Study of Respiratory Syncytial Virus Prophylaxis in Korean Children with Congenital Heart Diseases.
P2860
Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Palivizumab and the prevention ...... with congenital heart disease.
@en
type
label
Palivizumab and the prevention ...... with congenital heart disease.
@en
prefLabel
Palivizumab and the prevention ...... with congenital heart disease.
@en
P2860
P1476
Palivizumab and the prevention ...... with congenital heart disease.
@en
P2093
Henry M Sondheimer
Timothy F Feltes
P2860
P304
P356
10.1517/14712598.7.9.1471
P407
P577
2007-09-01T00:00:00Z